Article Information
History
- May 10, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Nataliia Khanyk1,2,*,
- Fredrik Nyberg3,
- Björn Wettermark1,
- Huiqi Li3,
- Katarina Eeg-Olofsson4,5,
- Soffia Gudbjornsdottir5 and
- Mohammadhossein Hajiebrahimi1
- 1Pharmacoepidemiology & Social Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden
- 2Department of Pharmacy, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
- 3School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- 4Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
- 5Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- ↵*Corresponding author:
Nataliia Khanyk nataliia.khanyk{at}farmaci.uu.se Biomedicinskt Centrum BMC, Husargatan 3, 752 37, Uppsala
Posted May 10, 2024.
Impact of the COVID-19 pandemic on antidiabetic drugs initiation in Sweden, an interrupted time series study
